Can Aspirin Help Prevent Ovarian Cancer?

A recent study conducted by the National Cancer Institute has shown that daily aspirin use may reduce the risk of ovarian cancer by %20.

New evidence suggests that daily aspirin use may reduce the risk of ovarian cancer. However, more research on aspirin is needed before it can be used regularly as a method of prevention for this type of cancer.

Aspirin taken daily at a low dose may help reduce the risk of some serious diseases. Previous research has shown that aspirin may help protect against cardiovascular diseases and certain types of cancer, such as bladder, breast, liver, and lung cancer. It may now be possible to add ovarian cancer to this list.

A recent study conducted by the National Cancer Institute has shown that daily aspirin use may reduce the risk of ovarian cancer by %20. In fact, aspirin was observed to reduce the risk even further when used at a low dose.

Every new finding related to preventing any type of cancer is good news. However, when it comes to ovarian cancer, every promising way to reduce the risk is important. This is because there is no standard imaging measure for this disease, and its symptoms can present similarly to gastrointestinal diseases and other common health problems. As a result, ovarian cancer may not be diagnosed until it reaches an advanced stage that is difficult to treat.

In this case, how does aspirin affect ovarian cancer? Medicines that fight inflammation in the body, such as aspirin and other non-aspirin pain relievers (nonsteroidal anti-inflammatory drugs—anti-inflammatory medicines), may help reduce the risk of inflammation-related diseases as well as cancer, diabetes, and cardiovascular diseases.

The National Cancer Institute and the researchers evaluated women who used aspirin, other non-aspirin pain relievers (such as ibufen, apranax, and voltaren), or parol in order to measure their effect on reducing the risk of ovarian cancer. At the end of the study, it was concluded that women who used aspirin daily had a %20 reduction in their risk of ovarian cancer compared with women who used aspirin less frequently, and that this risk reduction increased with low-dose aspirin use.

The study found that aspirin use was the most effective way to reduce the risk compared with other non-aspirin pain relievers (such as ibufen, apranax, and voltaren) or parol. A reduction in the risk of ovarian cancer was also observed in women who used other non-aspirin pain relievers. However, this reduction was around %20 with aspirin, while it remained at %10 with non-aspirin pain relievers. In addition, parol was found not to reduce the risk of ovarian cancer because it is not an anti-inflammatory medicine.

Nevertheless, it is still too early for aspirin to be considered a proven preventive measure against ovarian cancer. For now, the good news is that daily aspirin use approved by your doctor to reduce the risk of other diseases may also reduce the risk of ovarian cancer.